Literature DB >> 1386138

Increasing scientific power with statistical power.

K E Muller1, V A Benignus.   

Abstract

A survey of basic ideas in statistical power analysis demonstrates the advantages and ease of using power analysis throughout the design, analysis, and interpretation of research. The power of a statistical test is the probability of rejecting the null hypothesis of the test. The traditional approach to power involves computation of only a single power value. The more general power curve allows examining the range of power determinants, which are sample size, population difference, and error variance, in traditional ANOVA. Power analysis can be useful not only in study planning, but also in the evaluation of existing research. An important application is in concluding that no scientifically important treatment difference exists. Choosing an appropriate power depends on: a) opportunity costs, b) ethical trade-offs, c) the size of effect considered important, d) the uncertainty of parameter estimates, and e) the analyst's preferences. Although precise rules seem inappropriate, several guidelines are defensible. First, the sensitivity of the power curve to particular characteristics of the study, such as the error variance, should be examined in any power analysis. Second, just as a small type I error rate should be demonstrated in order to declare a difference nonzero, a small type II error should be demonstrated in order to declare a difference zero. Third, when ethical and opportunity costs do not preclude it, power should be at least .84, and preferably greater than .90.

Entities:  

Mesh:

Year:  1992        PMID: 1386138     DOI: 10.1016/0892-0362(92)90019-7

Source DB:  PubMed          Journal:  Neurotoxicol Teratol        ISSN: 0892-0362            Impact factor:   3.763


  13 in total

1.  BIAS IN LINEAR MODEL POWER AND SAMPLE SIZE DUE TO ESTIMATING VARIANCE.

Authors:  Keith E Muller; Virginia B Pasour
Journal:  Commun Stat Theory Methods       Date:  1997       Impact factor: 0.893

2.  Improving Functional Performance and Muscle Power 4-to-6 Months After Anterior Cruciate Ligament Reconstruction.

Authors:  Sabrine Souissi; Del P Wong; Alexandre Dellal; Jean-Louis Croisier; Zied Ellouze; Karim Chamari
Journal:  J Sports Sci Med       Date:  2011-12-01       Impact factor: 2.988

3.  Computing Confidence Bounds for Power and Sample Size of the General Linear Univariate Model.

Authors:  Douglas J Taylor; Keith E Muller
Journal:  Am Stat       Date:  1995-01-01       Impact factor: 8.710

4.  POWERLIB: SAS/IML Software for Computing Power in Multivariate Linear Models.

Authors:  Jacqueline L Johnson; Keith E Muller; James C Slaughter; Matthew J Gurka; Matthew J Gribbin; Sean L Simpson
Journal:  J Stat Softw       Date:  2009-04-01       Impact factor: 6.440

5.  Power Calculations for General Linear Multivariate Models Including Repeated Measures Applications.

Authors:  Keith E Muller; Lisa M Lavange; Sharon Landesman Ramey; Craig T Ramey
Journal:  J Am Stat Assoc       Date:  1992-12-01       Impact factor: 5.033

6.  Genome-wide expression profiling in the peripheral blood of patients with fibromyalgia.

Authors:  Kim D Jones; Terri Gelbart; Thomas C Whisenant; Jill Waalen; Tony S Mondala; David N Iklé; Daniel R Salomon; Robert M Bennett; Sunil M Kurian
Journal:  Clin Exp Rheumatol       Date:  2016-02-12       Impact factor: 4.473

7.  A method for determination of optimal image enhancement for the detection of mammographic abnormalities.

Authors:  D T Puff; E D Pisano; K E Muller; R E Johnston; B M Hemminger; C A Burbeck; R McLelland; S M Pizer
Journal:  J Digit Imaging       Date:  1994-11       Impact factor: 4.056

8.  Use of biomarkers of collagen types I and III fibrosis metabolism to detect cardiovascular and renal disease in chimpanzees (Pan troglodytes).

Authors:  John J Ely; Micah A Bishop; Michael L Lammey; Meg M Sleeper; Jörg M Steiner; D Rick Lee
Journal:  Comp Med       Date:  2010-04       Impact factor: 0.982

Review 9.  Methods to identify and characterize developmental neurotoxicity for human health risk assessment. I: behavioral effects.

Authors:  D A Cory-Slechta; K M Crofton; J A Foran; J F Ross; L P Sheets; B Weiss; B Mileson
Journal:  Environ Health Perspect       Date:  2001-03       Impact factor: 9.031

10.  Statistical power considerations show the endocrine disruptor low-dose issue in a new light.

Authors:  Martin Scholze; Andreas Kortenkamp
Journal:  Environ Health Perspect       Date:  2007-12       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.